Cyclo Therapeutics Return on Equity

Cyclo Therapeutics (CYTH) currently reports a ROE of 184.06%. That is above the Healthcare sector average of 11.15%. Use the charts on this page to explore Cyclo Therapeutics's ROE history and peer comparisons.

Cyclo Therapeutics's ROE of 184.06% is higher than the Healthcare sector average of 11.15%. That is roughly 1550.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Cyclo Therapeutics's current 184.06% should be judged against Healthcare norms (sector average: 11.15%) and against CYTH's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 184.06%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 11.15%. From there, open related valuation or income-statement pages for Cyclo Therapeutics, and consider following CYTH for alerts when major investors trade the stock.

Cyclo Therapeutics is classified in the Healthcare sector. On ROE, it currently shows 184.06% versus a sector average near 11.15%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing CYTH with unrelated industries.